Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells - PubMed

Review

Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells

G J Wiederrecht et al. Prog Cell Cycle Res. 1995.

Abstract

The immunosuppressant drug, rapamycin (RAP), is a potent inhibitor of IL-2-dependent T-cell proliferation. The antiproliferative effect of RAP is mediated through the formation of an active complex with its cytosolic receptor protein, FKBP12. The molecular target of the FKBP12.RAP complex is a putative lipid kinase termed the mammalian Target Of Rapamycin (mTOR). This review will discuss recent findings suggesting that mTOR is a novel regulator of G1- to S-phase progression in eukaryotic cells.

Similar articles

• Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.

  Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT. Sabers CJ, et al. J Biol Chem. 1995 Jan 13;270(2):815-22. doi: 10.1074/jbc.270.2.815. J Biol Chem. 1995. PMID: 7822316

• Mechanism of action of the immunosuppressant rapamycin.

  Dumont FJ, Su Q. Dumont FJ, et al. Life Sci. 1996;58(5):373-95. doi: 10.1016/0024-3205(95)02233-3. Life Sci. 1996. PMID: 8594303 Review.

• Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling.

  Abraham RT. Abraham RT. Curr Opin Immunol. 1998 Jun;10(3):330-6. doi: 10.1016/s0952-7915(98)80172-6. Curr Opin Immunol. 1998. PMID: 9638370 Review.

• A mammalian protein targeted by G1-arresting rapamycin-receptor complex.

  Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. Brown EJ, et al. Nature. 1994 Jun 30;369(6483):756-8. doi: 10.1038/369756a0. Nature. 1994. PMID: 8008069

• TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin.

  Zheng XF, Florentino D, Chen J, Crabtree GR, Schreiber SL. Zheng XF, et al. Cell. 1995 Jul 14;82(1):121-30. doi: 10.1016/0092-8674(95)90058-6. Cell. 1995. PMID: 7606777

Cited by

• Sirolimus reduces T cell cycling, immune checkpoint marker expression, and HIV-1 DNA in people with HIV.

  Henrich TJ, Bosch RJ, Godfrey C, Mar H, Nair A, Keefer M, Fichtenbaum C, Moisi D, Clagett B, Buck AM, Deitchman AN, Aweeka F, Li JZ, Kuritzkes DR, Lederman MM, Hsue PY, Deeks SG; ACTG A5337 Team. Henrich TJ, et al. Cell Rep Med. 2024 Oct 15;5(10):101745. doi: 10.1016/j.xcrm.2024.101745. Epub 2024 Sep 24. Cell Rep Med. 2024. PMID: 39321793 Free PMC article.

• Kaempferol attenuates imiquimod-induced psoriatic skin inflammation in a mouse model.

  Liu C, Liu H, Lu C, Deng J, Yan Y, Chen H, Wang Y, Liang CL, Wei J, Han L, Dai Z. Liu C, et al. Clin Exp Immunol. 2019 Dec;198(3):403-415. doi: 10.1111/cei.13363. Epub 2019 Aug 26. Clin Exp Immunol. 2019. PMID: 31407330 Free PMC article.

• Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours.

  Martin-Liberal J, Gil-Martín M, Sáinz-Jaspeado M, Gonzalo N, Rigo R, Colom H, Muñoz C, Tirado OM, García del Muro X. Martin-Liberal J, et al. Br J Cancer. 2014 Aug 26;111(5):858-65. doi: 10.1038/bjc.2014.370. Epub 2014 Jul 8. Br J Cancer. 2014. PMID: 25003665 Free PMC article. Clinical Trial.

• The role of mTOR inhibitors for treatment of sarcomas.

  Mita MM, Tolcher AW. Mita MM, et al. Curr Oncol Rep. 2007 Jul;9(4):316-22. doi: 10.1007/s11912-007-0039-7. Curr Oncol Rep. 2007. PMID: 17588357 Review.

• Biotic acts of antibiotics.

  Aminov RI. Aminov RI. Front Microbiol. 2013 Aug 19;4:241. doi: 10.3389/fmicb.2013.00241. eCollection 2013. Front Microbiol. 2013. PMID: 23966991 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Molecular Biology Databases

  • Saccharomyces Genome Database

• Miscellaneous

  • NCI CPTAC Assay Portal